Company: PSTV
Filing Date: 2025-04-01
Form Type: PRER14A
Source: 0001140361-25-011649
Chunk: 27

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-01
Form: PRER14A
Chunk 27
---
 in accordance with the terms of the Warrants and Prefunded Warrants. Any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, however, upon at least sixty-one (61) days’ prior notice from the holder to us with respect to any increase in such percentage.

Exercise Price . The exercise price of each Prefunded Warrant is $0.001 per share of Common Stock.

The initial exercise price of each Series A Warrant is $1.32 per share of Common Stock.

The initial exercise price of each Series B Warrant is $1.98 per share of Common Stock or pursuant to a zero exercise price option.

Reset Provision . The exercise price of the Warrants will reset to a price equal to the greater of (i) the Floor Price, and (ii) the lowest volume weighted average price (“VWAP”) during the period commencing on the first trading day immediately following the later of (x) the earlier of (A) the first (1 st) trading day after the initial registration statement that we are required to file to register the resale of the securities in the Private Placement, or (B) the first (1 st) trading day after the date on which the holder of those securities can sell them pursuant to Rule 144 without restriction or limitation, or (y) the first (1 st) Trading Day after the Warrant Stockholder Approval is obtained, and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate exercise price will remain unchanged. The Floor Price is subject to appropriate adjustment for any stock dividend, stock split, stock combination, reclassification or similar transaction.

In the event that the exercise price of the Series A Warrants and Series B Warrants is reduced to the Floor Price pursuant to the reset provision, 28,042,140 outstanding Series A Warrants would be exercisable for an aggregate of up to 280,421,380 shares of Common Stock and 28,042,140 outstanding Series B Warrants would be exercisable for an aggregate of up to 420,632,070 shares of Common Stock, or up to 1,261,896,210 shares of Common Stock if the Series B Warrants are exercised pursuant to the zero exercise price provision.

Adjustment for Subsequent Issuances . Subject to certain exceptions, if the Company sells any Common Stock (or securities convertible into or exercisable into Common Stock) at a price per share (or conversion or exercise price, as applicable